# Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

> **NCT02899052** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 120 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Venetoclax
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02899052
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-01-19
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899052, "Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02899052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*